(Q54349347)

English

A phase II study of metronomic paclitaxel/cyclophosphamide/capecitabine followed by 5-fluorouracil/epirubicin/cyclophosphamide as preoperative chemotherapy for triple-negative or low hormone receptor expressing/HER2-negative primary breast cancer.

scientific article

In more languages

default values for all languages

No label defined

No description defined

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

28 May 2018

http://europepmc.org/abstract/MED/24871032

A phase II study of metronomic paclitaxel/cyclophosphamide/capecitabine followed by 5-fluorouracil/epirubicin/cyclophosphamide as preoperative chemotherapy for triple-negative or low hormone receptor expressing/HER2-negative primary breast cancer. (English)

1 reference

Europe PubMed Central

PubMed publication ID

28 May 2018

http://europepmc.org/abstract/MED/24871032

preoperative chemotherapy

1 reference

based on heuristic

inferred from title

author name string

N Masuda

1

1 reference

Europe PubMed Central

PubMed publication ID

28 May 2018

http://europepmc.org/abstract/MED/24871032

K Higaki

2

1 reference

Europe PubMed Central

PubMed publication ID

28 May 2018

http://europepmc.org/abstract/MED/24871032

T Takano

3

1 reference

Europe PubMed Central

PubMed publication ID

28 May 2018

http://europepmc.org/abstract/MED/24871032

N Matsunami

4

1 reference

Europe PubMed Central

PubMed publication ID

28 May 2018

http://europepmc.org/abstract/MED/24871032

T Morimoto

5

1 reference

Europe PubMed Central

PubMed publication ID

28 May 2018

http://europepmc.org/abstract/MED/24871032

S Ohtani

6

1 reference

Europe PubMed Central

PubMed publication ID

28 May 2018

http://europepmc.org/abstract/MED/24871032

M Mizutani

7

1 reference

Europe PubMed Central

PubMed publication ID

28 May 2018

http://europepmc.org/abstract/MED/24871032

T Miyamoto

8

1 reference

Europe PubMed Central

PubMed publication ID

28 May 2018

http://europepmc.org/abstract/MED/24871032

K Kuroi

9

1 reference

Europe PubMed Central

PubMed publication ID

28 May 2018

http://europepmc.org/abstract/MED/24871032

S Ohno

10

1 reference

Europe PubMed Central

PubMed publication ID

28 May 2018

http://europepmc.org/abstract/MED/24871032

S Morita

11

1 reference

Europe PubMed Central

PubMed publication ID

28 May 2018

http://europepmc.org/abstract/MED/24871032

M Toi

12

1 reference

Europe PubMed Central

PubMed publication ID

28 May 2018

http://europepmc.org/abstract/MED/24871032

publication date

29 May 2014

1 reference

Europe PubMed Central

PubMed publication ID

28 May 2018

http://europepmc.org/abstract/MED/24871032

Cancer Chemotherapy and Pharmacology

1 reference

Europe PubMed Central

PubMed publication ID

28 May 2018

http://europepmc.org/abstract/MED/24871032

74

1 reference

Europe PubMed Central

PubMed publication ID

28 May 2018

http://europepmc.org/abstract/MED/24871032

2

1 reference

Europe PubMed Central

PubMed publication ID

28 May 2018

http://europepmc.org/abstract/MED/24871032

229-238

1 reference

Europe PubMed Central

PubMed publication ID

28 May 2018

http://europepmc.org/abstract/MED/24871032

Clinicopathological analyses of triple negative breast cancer using surveillance data from the Registration Committee of the Japanese Breast Cancer Society

1 reference

https://api.crossref.org/works/10.1007%2FS00280-014-2492-Y

21 January 2018

Triple negative breast cancer: current understanding of biology and treatment options

1 reference

https://api.crossref.org/works/10.1007%2FS00280-014-2492-Y

21 January 2018

Descriptive analysis of estrogen receptor (ER)-negative, progesterone receptor (PR)-negative, and HER2-negative invasive breast cancer, the so-called triple-negative phenotype: a population-based study from the California cancer Registry

1 reference

https://api.crossref.org/works/10.1007%2FS00280-014-2492-Y

21 January 2018

Response to neoadjuvant therapy and long-term survival in patients with triple-negative breast cancer

1 reference

https://api.crossref.org/works/10.1007%2FS00280-014-2492-Y

21 January 2018

p53 status and efficacy of primary anthracyclines/alkylating agent-based regimen according to breast cancer molecular classes

1 reference

https://api.crossref.org/works/10.1007%2FS00280-014-2492-Y

21 January 2018

The triple negative paradox: primary tumor chemosensitivity of breast cancer subtypes

1 reference

https://api.crossref.org/works/10.1007%2FS00280-014-2492-Y

21 January 2018

Prognostic impact of clinicopathologic parameters in stage II/III breast cancer treated with neoadjuvant docetaxel and doxorubicin chemotherapy: paradoxical features of the triple negative breast cancer

1 reference

https://api.crossref.org/works/10.1007%2FS00280-014-2492-Y

21 January 2018

Breast cancer molecular subtypes respond differently to preoperative chemotherapy

1 reference

https://api.crossref.org/works/10.1007%2FS00280-014-2492-Y

21 January 2018

Triple-negative breast cancer: therapeutic options

1 reference

https://api.crossref.org/works/10.1007%2FS00280-014-2492-Y

21 January 2018

Metronomic oral combination chemotherapy with capecitabine and cyclophosphamide: a phase II study in patients with HER2-negative metastatic breast cancer.

1 reference

https://api.crossref.org/works/10.1007%2FS00280-014-2492-Y

21 January 2018

Superior survival with capecitabine plus docetaxel combination therapy in anthracycline-pretreated patients with advanced breast cancer: phase III trial results

1 reference

https://api.crossref.org/works/10.1007%2FS00280-014-2492-Y

21 January 2018

Low dose capecitabine plus weekly paclitaxel in patients with metastatic breast cancer: a multicenter phase II study KBCSG-0609.

1 reference

https://api.crossref.org/works/10.1007%2FS00280-014-2492-Y

21 January 2018

Phase I study of combination therapy with weekly paclitaxel and cyclophosphamide for advanced or recurrent breast cancer

1 reference

https://api.crossref.org/works/10.1007%2FS00280-014-2492-Y

21 January 2018

Metronomic cyclophosphamide and capecitabine combined with bevacizumab in advanced breast cancer.

1 reference

https://api.crossref.org/works/10.1007%2FS00280-014-2492-Y

21 January 2018

Overall survival benefit for weekly vs. three-weekly taxanes regimens in advanced breast cancer: A meta-analysis

1 reference

https://api.crossref.org/works/10.1007%2FS00280-014-2492-Y

21 January 2018

A comparative analysis of low-dose metronomic cyclophosphamide reveals absent or low-grade toxicity on tissues highly sensitive to the toxic effects of maximum tolerated dose regimens

1 reference

https://api.crossref.org/works/10.1007%2FS00280-014-2492-Y

21 January 2018

Metronomic low-dose oral cyclophosphamide and methotrexate plus or minus thalidomide in metastatic breast cancer: antitumor activity and biological effects.

1 reference

https://api.crossref.org/works/10.1007%2FS00280-014-2492-Y

21 January 2018

Reappraising antiangiogenic therapy for breast cancer

1 reference

https://api.crossref.org/works/10.1007%2FS00280-014-2492-Y

21 January 2018

Issues in the assessment of the pathologic effect of primary systemic therapy for breast cancer

1 reference

https://api.crossref.org/works/10.1007%2FS00280-014-2492-Y

21 January 2018

Weekly paclitaxel improves pathologic complete remission in operable breast cancer when compared with paclitaxel once every 3 weeks

1 reference

https://api.crossref.org/works/10.1007%2FS00280-014-2492-Y

21 January 2018

Low-dose metronomic chemotherapy: a systematic literature analysis

1 reference

https://api.crossref.org/works/10.1007%2FS00280-014-2492-Y

21 January 2018

Neoadjuvant chemotherapy and bevacizumab for HER2-negative breast cancer.

1 reference

https://api.crossref.org/works/10.1007%2FS00280-014-2492-Y

21 January 2018

Randomized Phase III Trial of Weekly Compared With Every-3-Weeks Paclitaxel for Metastatic Breast Cancer, With Trastuzumab for all HER-2 Overexpressors and Random Assignment to Trastuzumab or Not in HER-2 Nonoverexpressors: Final Results of Cancer an

1 reference

https://api.crossref.org/works/10.1007%2FS00280-014-2492-Y

21 January 2018

Randomized Phase II Trial of Letrozole and Letrozole Plus Low-Dose Metronomic Oral Cyclophosphamide As Primary Systemic Treatment in Elderly Breast Cancer Patients

1 reference

https://api.crossref.org/works/10.1007%2FS00280-014-2492-Y

21 January 2018

Identifiers

10.1007/S00280-014-2492-Y

1 reference

Europe PubMed Central

PubMed publication ID

28 May 2018

http://europepmc.org/abstract/MED/24871032

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

28 May 2018

http://europepmc.org/abstract/MED/24871032

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q54349347&oldid=2212435207"